Latest Period
Q1 2026
Security Snapshot
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) Institutional Ownership
CUSIP: 75383L102
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
146
Shares (Excl. Options)
52,482,926
Price
$31.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- RAPP on Nasdaq
- Shares outstanding
- 47,779,015
- Price per share
- $36.95
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 52,482,926
- Total reported value
- $1,641,485,641
- % of total 13F portfolios
- 0%
- Share change
- +1,311,094
- Value change
- +$41,369,915
- Number of holders
- 146
- Price from insider filings
- $36.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 75383L102.
- 146 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 144 to 146 between Q4 2025 and Q1 2026.
- Reported value moved from $1,549,894,668 to $1,641,485,641.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 146 institutions filings for Q1 2026.
Security key
75383L102
Latest holder period
Q1 2026
13F holders
146
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
RAPP full holder history
Rapport Therapeutics, Inc. SEC filings
Rapport Therapeutics, Inc. company facts
Rapport Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75383L102:
Significant Owners of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 20% | $81,198,952 | 7,135,233 | Third Rock Ventures V, L.P. | 31 Dec 2024 | |||
| Cormorant Asset Management, LP | 6.2% | -2.7% | $99,047,378 | -$2,344,300 | 2,957,521 | -2.3% | Cormorant Asset Management, LP | 31 Mar 2026 |
| BlackRock, Inc. | 5% | $72,741,637 | 2,397,549 | BlackRock, Inc. | 31 Dec 2025 | |||
| Sofinnova Venture Partners XI, L.P. | 4.2% | $29,155,258 | 1,947,579 | Dr. James I. Healy ("Healy") | 11 Sep 2025 | |||
| JOHNSON & JOHNSON | 4.9% | $53,000,690 | 1,784,517 | JOHNSON & JOHNSON | 30 Sep 2025 |
As of 31 Mar 2026, 146 institutional investors reported holding 52,482,926 shares of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP). This represents 110% of the company’s total 47,779,015 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) together control 99% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 7,168,939 | +0.8% | 0.01% | $224,316,101 |
| TRV GP V, LLC | 15% | 7,135,233 | 0% | 56% | $223,261,441 |
| ARCH Venture Management, LLC | 7.8% | 3,728,738 | 0% | 17% | $116,672,212 |
| Capital International Investors | 6.5% | 3,097,973 | -9% | 0.02% | $96,935,575 |
| Cormorant Asset Management, LP | 6.2% | 2,957,521 | -2.3% | 4.7% | $92,540,832 |
| GOLDMAN SACHS GROUP INC | 6.2% | 2,942,251 | -2% | 0.01% | $92,063,034 |
| BlackRock, Inc. | 5.2% | 2,505,955 | +3% | 0% | $78,411,332 |
| Sofinnova Investments, Inc. | 4% | 1,904,408 | 0% | 3% | $59,588,926 |
| JOHNSON & JOHNSON | 3.7% | 1,784,517 | 0% | 8.6% | $55,837,537 |
| Polar Capital Holdings Plc | 3.4% | 1,642,461 | +63% | 0.22% | $51,392,605 |
| BAKER BROS. ADVISORS LP | 3.2% | 1,547,090 | 0% | 0.28% | $48,408,446 |
| Vestal Point Capital, LP | 3% | 1,436,229 | +29% | 1.3% | $44,939,605 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.8% | 1,325,082 | 0% | 0% | $41,461,816 |
| TRV GP VI, LLC | 2% | 969,218 | 0% | 22% | $30,326,831 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.9% | 918,866 | -3.5% | 0.01% | $28,751,317 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 866,456 | -1.7% | 0% | $27,112,000 |
| STATE STREET CORP | 1.6% | 759,552 | +6.3% | 0% | $23,766,382 |
| ALLIANCEBERNSTEIN L.P. | 1.5% | 727,843 | -7.7% | 0.01% | $22,082,757 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 721,622 | +3.9% | 0% | $22,583,176 |
| PERCEPTIVE ADVISORS LLC | 1.4% | 673,923 | 0% | 0.42% | $21,087,051 |
| Siren, L.L.C. | 1.3% | 641,469 | -9.5% | 0.56% | $20,071,565 |
| T. Rowe Price Investment Management, Inc. | 1.3% | 620,600 | +0.25% | 0.01% | $19,419,000 |
| Capital World Investors | 1.1% | 536,607 | 0% | $16,790,433 | |
| Sio Capital Management, LLC | 0.77% | 366,809 | +98% | 1.7% | $11,477,454 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.67% | 320,909 | 0% | 0% | $10,041,243 |
Institutional Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 52,482,926 | $1,641,485,641 | +$41,369,915 | $31.29 | 146 |
| 2025 Q4 | 51,084,271 | $1,549,894,668 | +$54,540,100 | $30.34 | 144 |
| 2025 Q3 | 49,276,697 | $1,463,478,389 | +$335,895,056 | $29.70 | 123 |
| 2025 Q2 | 38,494,803 | $437,875,302 | +$4,896,059 | $11.37 | 81 |
| 2025 Q1 | 38,102,588 | $382,320,591 | +$11,241,443 | $10.03 | 77 |
| 2024 Q4 | 36,577,539 | $648,890,836 | -$29,671 | $17.74 | 69 |
| 2024 Q3 | 28,444,042 | $581,877,476 | +$37,552,009 | $20.48 | 55 |
| 2024 Q2 | 25,558,517 | $593,435,106 | +$593,435,106 | $23.26 | 35 |